Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

OP40

Sigma-Aldrich

Anti-Pan-Ras (Ab-3) Mouse mAb (RAS 10)

liquid, clone RAS 10, Calbiochem®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Código UNSPSC:
12352203
NACRES:
NA.43

origen biológico

mouse

Nivel de calidad

forma del anticuerpo

purified antibody

tipo de anticuerpo

primary antibodies

clon

RAS 10, monoclonal

Formulario

liquid

contiene

≤0.1% sodium azide as preservative

reactividad de especies

human, mouse, rat

fabricante / nombre comercial

Calbiochem®

condiciones de almacenamiento

do not freeze

isotipo

IgG2a

Condiciones de envío

wet ice

temp. de almacenamiento

2-8°C

modificación del objetivo postraduccional

unmodified

Información sobre el gen

human ... KRAS(3845)

Descripción general

Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2/0 myeloma cells (see application references). Recognizes the ~21 kDa Ras protein.
Recognizes the ~21 kDa H-, K-, and N-Ras proteins in SW480 and Y1 cells and breast carcinoma tissue.
This Anti-Pan-Ras (Ab-3) Mouse mAb (RAS 10) is validated for use in FC, Frozen Sections, Immunoblotting, IF, IP, Paraffin Sections for the detection of Pan-Ras (Ab-3).

Inmunógeno

recombinant human p21 Ras

Aplicación


Flow Cytometry (2.5 g/ml)
Frozen Sections (2.5 g/ml)
Immunoblotting (0.1-3 g/ml, chemiluminescent and colorimetric, see application references)
Immunofluorescence (2.5 g/ml, see application references)
Immunoprecipitation (1 g/sample)
Paraffin Sections (2.5 g/ml, saponin pre-treatment required)

Envase

Please refer to vial label for lot-specific concentration.

Advertencia

Toxicity: Standard Handling (A)

Nota de análisis

Positive Control
SW480 or Y1 cells or breast carcinoma tissue

Otras notas

Rodenhuis, S. et al., 1992. Cancer Res. (Suppl)52, 2665s.
Sidransky, D., et al. 1992. Science256, 102.
Hamer, P.J., et al. 1990. Hybridoma9, 573.
Bos, J.L. 1989. Cancer Res.49, 4682.
Furth, M. E., et al. 1987. Oncogene1, 47.
Kraus, M.H., et al. 1984. Proc. Natl. Acad. Sci. USA81, 5384.
Shimizu, K., et al. 1983. Proc. Natl. Acad. Sci. USA80, 2112.
Taparowsky, E., et al. 1983. Cell34, 581.
Ellis, R.W., et al. 1981. Nature292, 506.
Shih, T.Y., et al. 1980. Nature287, 686.
The level of expression of p21ras is variable in different tissues. For this reason we recommend a concentration step prior to immunoblot analysis to obtain optimal results. Antibody should be titrated for optimal results in individual systems.

Información legal

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

J M English et al.
The Journal of biological chemistry, 274(44), 31588-31592 (1999-10-26)
The activity of the catalytic domain of the orphan MAP kinase ERK5 is increased by Ras but not Raf-1 in cells, which suggests that ERK5 might mediate Raf-independent signaling by Ras. We found that Raf-1 does contribute to Ras activation
J M English et al.
The Journal of biological chemistry, 273(7), 3854-3860 (1998-03-28)
Extracellular signal-regulated protein kinase 5 (ERK5) is a recently discovered orphan mitogen-activated protein kinase for which no substrates or strong activators have been described. Two ERK5 chimeras were created as a novel approach to discover its substrates and upstream regulators.
Alisa Morshneva et al.
Cells, 9(1) (2020-01-08)
The adenoviral early region 1A (E1A) protein has proapoptotic and angiogenic activity, along with its chemosensitizing effect, making it the focus of increased interest in the context of cancer therapy. It was previously shown that E1A-induced chemosensitization to different drugs
Lauren L Fonseca et al.
Translational oncology, 14(1), 100880-100880 (2020-10-20)
Ras mutations are present in only a subset of sporadic human cutaneous squamous cell carcinomas (cSCC) even though Ras is activated in most. This suggests that other mechanisms of Ras activation play a role in the disease. The aberrant expression
Qing-Fen Li et al.
Cell reports, 24(11), 2869-2882 (2018-09-13)
Cerebrovascular malformations (CVMs) affect approximately 3% of the population, risking hemorrhagic stroke, seizures, and neurological deficits. Recently Ras mutations have been identified in a majority of brain arterio-venous malformations. We generated an endothelial-specific, inducible HRASV12 mouse model, which results in

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico